Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Fulvestrant
Drug ID BADD_D00978
Description Fulvestrant is a drug treatment of hormone receptor (HR)-positive metastatic breast cancer in post-menopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects, which works both by down-regulating and by degrading the estrogen receptor. While it is used as monotherapy for the treatment of breast cancers, it is also used in combination with [alpelisib] for the treatment of HR-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer
Indications and Usage For the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy.
Marketing Status Prescription
ATC Code L02BA03
DrugBank ID DB00947
KEGG ID D01161
MeSH ID D000077267
PubChem ID 104741
TTD Drug ID D0JO7Y
NDC Product Code 64918-1402; 16714-118; 68001-522; 16729-436; 16714-070; 68001-484; 0310-7720; 70860-211; 71731-6121; 70121-1463; 43598-262; 70710-1688; 66529-0014; 68462-317; 70771-1626; 0591-5019; 72603-105; 50923-0416; 0143-9022; 70534-002; 0781-3492; 67457-311; 63323-715; 25021-462; 53183-9305; 68001-424; 65129-2149; 46439-8769; 59057-003; 61662-0011; 0781-3079; 0310-0720; 71288-555; 69910-0001; 68001-510; 70700-284; 58175-0600
Synonyms Fulvestrant | 7-(9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl)estra-1,3,5(10)-triene-3,17-diol | Faslodex | ICI 182780 | ICI 182,780 | ICI-182780 | ICI182780 | ZM 182780 | ZM-182780 | ZM182780
Chemical Information
Molecular Formula C32H47F5O3S
CAS Registry Number 129453-61-8
SMILES CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.002--
Abscess11.01.08.0010.002206%Not Available
Alanine aminotransferase increased13.03.01.0030.004413%
Alopecia23.02.02.0010.006619%
Anaemia01.03.02.001--
Anaphylactic reaction24.06.03.006; 10.01.07.0010.005884%
Anaphylactoid reaction24.06.03.007; 10.01.07.0030.002942%Not Available
Angioedema23.04.01.001; 10.01.05.009--Not Available
Anxiety19.06.02.002--
Arrhythmia02.03.02.001--Not Available
Arthralgia15.01.02.001--
Arthritis15.01.01.001--
Arthropathy15.01.01.0030.001471%Not Available
Ascites09.01.05.003; 07.07.01.001; 02.05.04.0020.003677%
Aspartate aminotransferase increased13.03.01.0060.004413%
Asthenia08.01.01.0010.013974%Not Available
Asthma22.03.01.002; 10.01.03.0100.002206%Not Available
Atrial fibrillation02.03.03.002--
Back pain15.03.04.0050.007355%
Basophil count increased13.01.06.0020.002206%Not Available
Blood bilirubin increased13.03.01.0080.004413%
Blood creatinine increased13.13.01.0040.002942%
Blood pressure decreased13.14.03.0020.004413%Not Available
Blood pressure increased13.14.03.005--Not Available
Body temperature increased13.15.01.001--Not Available
Bone pain15.02.01.0010.005148%
Breast cancer21.05.01.003; 16.10.01.0010.011032%Not Available
Breast cancer stage IV21.05.01.010; 16.10.01.003--Not Available
Bronchospasm22.03.01.004; 10.01.03.0120.002206%
Cardiac failure02.05.01.0010.000959%
The 1th Page    1 2 3 4 5    Next   Last    Total 10 Pages